Everything below concerns certificate of analysis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-01. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
=== Supercritical fluid chromatography === Supercritical fluid chromatography (SFC) can be used on an analytical scale, where it combines many of the advantages of high-performance liquid chromatography (HPLC) and gas chromatography (GC). It can be used with non-volatile and thermally labile analytes (unlike GC) and can be used with the universal flame ionization detector (unlike HPLC), as well as producing narrower peaks due to rapid diffusion. In practice, the advantages offered by SFC have not been sufficient to displace the widely used HPLC and GC, except in a few cases such as chiral separations and analysis of high-molecular-weight hydrocarbons. For manufacturing, efficient preparative simulated moving bed units are available. The purity of the final products is very high, but the cost makes it suitable only for very high-value materials such as pharmaceuticals.
On 13 December 1904, Hungarian Sándor Just and Croatian Franjo Hanaman were granted a Hungarian patent (No. 34541) for a tungsten filament lamp that lasted longer and gave brighter light than the carbon filament. Tungsten filament lamps were first marketed by the Hungarian company Tungsram in 1904. This type is often called Tungsram-bulbs in many European countries. Filling a bulb with an inert gas such as argon or nitrogen slows the evaporation of the tungsten filament compared to operating it in a vacuum. This allows for greater temperatures and therefore greater efficacy with less reduction in filament life. In 1906, William D. Coolidge developed a method of making "ductile tungsten" from sintered tungsten which could be made into filaments while working for General Electric Company. By 1911 General Electric had begun selling incandescent light bulbs with ductile tungsten wire. In 1913, Irving Langmuir found that filling a lamp with inert gas (nitrogen at first, and later argon) instead of a vacuum resulted in twice the luminous efficacy and reduced bulb blackening. He patented his device on April 18, 1916.
In normal conditions, the human intestine absorbs mainly nonphosphorylated B6 vitamers. The phosphorylated forms of B6 and the glucoside of pyridoxine can be hydrolyzed by intestinal phosphatases and an intestinal glycosidase, respectively, to promote passive diffusion of pyridoxamine, pyridoxine and pyridoxal. In the liver or intestine, they are then rephosphorylated by pyridoxal kinase (EC 2.7.1.35) to avoid inverse diffusion A transport protein / membrane carrier of PLP (and other phosphorylated forms of B6) is the human membrane enzyme NAPE-PLD N-acyl phosphatidylethanolamine-specific phospholipase D of the endocannabinoid system. In the presence of bile acids (e.g., digestion), NAPE-PLD with its internal channel creates membrane-pores as dynamic conductive pathways through which the charged cofactors of vitamin B6 can diffuse through cell membranes and membranes of subcellular compartments (e.g., mitochondria, peroxisome, and endosome), where they exert the specific enzymatic activities. NAPE-PLD is thus functional to the intracellular uptake and mobilization of PLP, and to the increased demand of the cofactor in pathological conditions having a higher endocannabinoid tone. Intracellular-free PLP concentrations are maintained at approximately 1 μM to prevent inappropriate reactions. Proteins that bind PLP and help maintain low-free PLP concentrations include glycogen phosphorylase in muscle, hemoglobin in erythrocytes, albumin in plasma, and NAPE-PLD mainly in the brain, gut, liver, kidney and reproductive system.
== Medical uses == Labetalol is effective in the management of hypertensive emergencies, postoperative hypertension, pheochromocytoma-associated hypertension, and rebound hypertension from beta blocker withdrawal. It has a particular indication in the treatment of pregnancy-induced hypertension which is commonly associated with pre-eclampsia. It is also used as an alternative in the treatment of severe hypertension. Labetalol is useful in the treatment of acute cardiovascular toxicity (e.g. in overdose) caused by sympathomimetics like amphetamine, methamphetamine, cocaine, ephedrine, and pseudoephedrine. Other beta blockers are also used. However, the controversial yet possible phenomenon of "unopposed α-stimulation" with administration of selective beta blockers to block non-selective sympathomimetics potentially makes dual alpha-1 and beta blockers like labetalol and carvedilol more favorable for such purposes. The rate of unopposed α-stimulation with selective beta blockers has been reported to be 0.4%, whereas no cases of unopposed α-stimulation have been reported with dual alpha and beta blockers like labetalol.
Sources: en.wikipedia.org
== Physical description == As in many chemical reactions, chemiluminescence starts with the combining of two compounds, say A and B, to give a product C. Unlike most chemical reactions, the product C converts to a further product, which is produced in an electronically excited state often indicated with an asterisk:
Chair of Trustees, Molly Rose Foundation. For services to Child Safety Online. Martin Henry Charles Russell, DL. For services to the community in the London Borough of Barnet. Rosemary Priscilla Irene Russell. Art and Design and Technology Technician, The Ursuline Academy Ilford. For services to Education and to Diversity in STEM. Elizabeth Joan Ryan. Lately Volunteer, Luton, South Bedfordshire and Harpenden Samaritans. For services to Suicide Prevention. Sadia Sadiq. Manager, Community Care and Wellbeing Services. For services to Minority Ethnic Communities in Wales. Lorraine Sanda. Strategic Director of People, Clackmannanshire Council. For services to Children and Families. Carolene Euleata Sargeant (Carolene Hinds). Independent Performing Arts Professional. For services to Dance. Professor William Peter Saunders. Chief Creative Officer, StoryFutures at Royal Holloway University. For services to the Creative Industries. Alison Melanie Savage. Officer Commanding, The Services Cotswold Centre. For services to Military Families. Jacqueline Savage. Volunteer. For services to Social Care. Majida Aly Sayam. Founder and Director, Jannaty Women's Social Society. For charitable services to Ethnic Minority Women. Kimberley Louise Scott. Lately Assistant Director of Education, Education Authority. For services to Education. Jacqueline Scrivens (Jacqueline Forester). Proprietor, The Woodshed Forest School Nursery. For services to Early Years Child-Lead Learning. Josephine Patricia Segal. Co-Founder, Spread a Smile.
== External links == American Association for Clinical Chemistry American Society for Clinical Pathology American Board of Pathology College of American Pathologists European Federation of Clinical Chemistry and Laboratory Medicine Academy of Clinical Laboratory Physicians and Scientists
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.